
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute is supported by a favorable FDA regulatory signal for ersodetug in congenital hyperinsulinism, where the agency recommended a pre-BLA meeting after its review of Phase 3 sunRIZE data and did not request an additional trial, improving the perceived path to approval. The clinical case is strengthened by consistent evidence of hypoglycemia reduction, continued glycemic benefit in the open-label extension for 9 months to 2 years, and meaningful reductions in background standard-of-care use, suggesting durable activity across hyperinsulinism populations. In tumor-associated hyperinsulinism, management disclosed seven responders among the first eight evaluable patients in upLIFT, leaving the study two responses away from the approximate nine needed for success among sixteen patients and reinforcing confidence in a positive readout.
Bears say
Rezolute is facing a poor risk-reward profile because its lead program could be halted by unforeseen safety or tolerability issues, which would immediately undermine the value of its single clinical asset. Even if development continues, the company could still lose commercial relevance if more efficacious products enter the market and capture share, limiting the eventual return on its rare-disease strategy. On top of that, Rezolute may fail to secure the financing needed for additional studies or commercialization, creating a material funding risk that could prevent the asset from reaching approval or meaningful revenue generation.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rezolute (RZLT) Forecast
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares